ID
45745
Beschrijving
Principal Investigator: Jean Claude Zenklusen, PhD, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Breast,Carcinoma, Renal Cell,Lymphoma, Large B-Cell, Diffuse https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001175 For the Clinical Trials Sequencing Project (CTSP), National Cancer Institute (NCI) will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent genetic alterations (mutations, deletions, amplifications, rearrangements) and/or gene expression signatures that would be important to the hypothesis(es) submitted by the investigators. The samples will be processed and submitted for genomic characterization using pipelines and procedures established within The Cancer Genome Analysis (TCGA) project. Data analysis will be performed as a collaboration between the National Clinical Trials Network (NCTN) Group and its investigators submitting the proposal. The investigators at the NCI-sponsored Genomic Data Analysis Center (GDAC) will characterize the samples. The NCTN Group will be responsible for providing the clinical data needed for the proposal to the open clinical system maintained by NCI CCG's Biospecimen Core Resource (BCR) at Nationwide Children's Hospital in Columbus, Ohio. The project team (Network Group/investigators and GDAC) will analyze the data together. Additionally, clinical and genomic data related to the analyses will also need to be registered by NCI and will be made available to qualified researchers via a controlled-access database (e.g., dbGaP) upon publication of the primary analysis described in the study proposal. A substudy description and its molecular data information are provided under its own page: phs001184 CTSP Diffuse Large B-Cell Lymphoma (DLBCL) CALGB 50303
Link
Trefwoorden
Versies (1)
- 02-06-23 02-06-23 - Chiara Middel
Houder van rechten
Jean Claude Zenklusen, PhD, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Geüploaded op
2 juni 2023
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs001175 CTSP: Clinical Trial Sequencing Project
The subject consent file includes subject IDs, consent information, and case control status of the subject for Diffuse Large B-Cell Lymphoma (DLBCL).
- StudyEvent: SEV1
- The subject consent file includes subject IDs, consent information, and case control status of the subject for Diffuse Large B-Cell Lymphoma (DLBCL).
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes substudy accession.
Similar models
The subject consent file includes subject IDs, consent information, and case control status of the subject for Diffuse Large B-Cell Lymphoma (DLBCL).
- StudyEvent: SEV1
- The subject consent file includes subject IDs, consent information, and case control status of the subject for Diffuse Large B-Cell Lymphoma (DLBCL).
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes substudy accession.
C0441833 (UMLS CUI [1,2])
C0242481 (UMLS CUI [1,2])
Geen commentaren